The 1 analysts offering 12-month price forecasts for Hepion Pharmaceuticals Inc have a median target of 2.50, with a high estimate of 2.50 and a low estimate of 2.50. The median estimate represents a +545.66% increase from the last price of 0.39.
The current consensus among 1 polled investment analysts is to Buy stock in Hepion Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.11
Reporting Date Nov 28
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.